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1040-8711 Copyright  2016 Wolte´Jacqueline Dekkers, Rene E.M. Toes, Tom W.J. Huizinga,
and Diane van der WoudePurpose of review
This review provides an update on the recent discoveries on the role of anticitrullinated protein antibodies
(ACPA) in early rheumatoid arthritis (RA).
Recent findings
RA is characterized by an immune response against posttranslationally modified proteins, in particular
citrullinated proteins. Recent studies have found that the ACPA response matures shortly before clinical
disease manifests itself and is characterized by an increase in titre, isotype switching, antigen-recognition
profile, and a change in the Fc-glycosylation pattern. To date, many citrullinated autoantigens have been
identified and novel studies suggest that the human leucocyte antigen class II locus may directly influence
the maturation of the ACPA response via antigen-specific T cells. Clinical studies have demonstrated that
effective treatment of arthritis can lead to reduced ACPA levels or a change in composition of ACPA. In
addition to ACPA, autoantibodies targeting other posttranslational modifications have been identified
and may be associated with disease prognosis.
Summary
Key studies have demonstrated that autoimmunity against citrullinated proteins is already present in
preclinical RA and matures over time. Future studies are required to reveal whether autoantibodies and
the B cells that produce them play a role in disease development or can function as biomarkers for
disease maturation.
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The identification of anticitrullinated protein
antibodies (ACPA) has had a major impact on the
understanding of rheumatoid arthritis (RA). In the
late 1990s, it was described for the first time that RA
patients produce autoantibodies that target peptides
and proteins containing citrulline, a modified form
of the amino-acid arginine [1,2]. Citrullination is a
posttranslational modification of protein-bound
arginine into citrulline residues which is mediated
by peptidyl arginine deiminase (PAD) enzymes and
is essential for the generation of antigens recognized
by ACPA [3]. Although the physiological role of
citrullination is not precisely known, it is clear
that this protein modification can occur during a
variety of biological processes, including inflam-
mation. Following the identification of citrullinated
proteins, several diagnostic tests were developed
based on cyclic citrullinated peptides (CCP) as a test Kluwer Health, Inc. Una
rs Kluwer Health, Inc. All rights resesubstrate for detecting ACPA. Using the CCP-assay,
a highly reliable diagnostic tool became available
for routine testing of antibodies directed against
citrullinated epitopes in early RA patients.
The presence of ACPA in the sera of patients
represents an important early biomarker and has
been added to the 2010 American College of Rheu-
matology/European League Against Rheumatism
(ACR/EULAR) classification criteria for RA [4]. The
selected parameters in the 2010 classificationuthorized reproduction of this article is prohibited.
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KEY POINTS
 Anticitrullinated protein antibodies (ACPA) can be
detected several years before disease onset and mature
over time with isotype switching and epitope spreading
occurring in the preclinical phase of disease.
 The specific association of ACPA-positive RA with
predisposing HLA alleles has fuelled hypotheses about
the involvement of citrulline-specific T cells in
RA pathogenesis.
 Autoantibodies in RA patients have now also been
found to recognize other posttranslational modifications
such as homocitrulline and malondialdehyde-
acetaldehyde.
Role of ACPA in early diseasecriteria were designed to include early markers
of disease rather than established clinical features
as was the case in the 1987 ACR guidelines. The
ACPA serology enables the clinician to identify
recent-onset RA patients earlier, which is crucial
for achieving timely control of disease progression.
Using the ACPA test it is possible to distinguish two
subclasses RA patients: ACPA-positive and ACPA-
negative. When comparing these two subclasses of
RA, major differences have been observed regarding
genetic and environmental risk factors, progression,
remission, and response to treatment. In this review,
we will provide an update on the latest findings
concerning the ACPA maturation profile, the associ-
ation between RA and the human leucocyte antigen
(HLA) DR-locus, and the hypotheses about disease
pathogenesis that contribute to a greater under-
standing of the role of ACPA in early RA.AUTOIMMUNITY RELATED TO
RHEUMATOID ARTHRITIS IS PRESENT
LONG BEFORE ONSET OF CLINICAL
SYMPTOMS
Autoantibodies are an important hallmark of RA
and several classes of autoantibodies have been
described that precede the development of RA,
including ACPA, rheumatoid factor and the recently
identified anticarbamylated protein antibodies
[5–7,8
&
]. Especially ACPA are of particular interest
as these autoantibodies are highly specific for RA
and can be found in about 50% of early RA patients.
The fact that ACPA are quite rare in healthy
individuals, suggests that autoantibody-positive
healthy individuals are at an increased risk of
developing RA [9
&&
]. These findings suggest that
ACPA and/or the underlying B-/T-cell responses play
a prominent role in disease pathogenesis. Shortly
before clinical onset of disease, there appears to beyright © 2016 Wolters Kluwer Health, Inc. Unaut
2 www.co-rheumatology.commaturation of the ACPA response which is charac-
terized by an increase in ACPA titre, isotype switch-
ing, an increased antigen-recognition profile, and a
change in Fc glycosylation pattern [10–14,15
&&
].
Different observations strongly suggest that the
development of ACPA-positive RA is based on a
two-hit model. Environmental triggers and epige-
netic stochastic events are thought to play a role in
the initial break of tolerance leading to the
formation of ACPA. A ‘second hit’, such as an infec-
tion or other factors, triggers the expansion of the




have indicated that the HLA molecules do not play a
considerable role during the first hit, but mainly
contribute to the second hit that enables the
expansion of the ACPA response.
ACPA can recognize a variety of citrullinated
antigens, including type II collagen, fibrinogen,
vimentin and many other citrullinated proteins.
An increase or shift of the antigen-recognition
profile, epitope spreading, can be a sign of
maturation of the antibody response and disease
progression. Epitope spreading is a hallmark of
maturation of the ACPA response and is predictive
for disease progression to early RA. After disease
onset, the increased citrullinated epitope-
recognition profile stabilizes and does not change
anymore [10]. A recent 2-year follow-up study
[17
&&
] enrolling 316 early RA patients in a Swedish
pharmacotherapy trial suggested that disappear-
ance of particular ACPA reactivities may be associ-
ated with a good treatment response in early RA.
These results differ from previous reports in which
the ACPA fine specificity did not seem to correlate
with disease activity, progression, or response to
therapy [18–20].
In the case of the response against recall anti-
gens, antibodies undergo class switching, somatic
hypermutation and affinity maturation to improve
the immune reaction against the antigen.
The variable region of ACPA has undergone
extensive somatic hypermutation, indicative of
a T-cell-dependent B-cell response [21]. The avid-
ity maturation of ACPA, however, appears to be
different from recall antigens. As compared with
antibodies against recall antigens, ACPA display a
considerably lower avidity and the ACPA response
shows only limited avidity maturation over time
[22,23]. The presence of these low-avidity ACPA in
RA patients is associated with a higher rate of joint
destruction. ACPA can activate the complement
system and can therefore play a role in the com-
plement-mediated recruitment of inflammatory
cells [24], which suggests that ACPA could be
directly involved in the disease process. Moreover,horized reproduction of this article is prohibited.
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IgA rheumatoid factor can directly trigger Fcg
receptors on macrophages and mast cells leading
to the production of proinflammatory cytokines





Maturation of antibody responses leads to a shift
in isotype which enables the activation of other
immune effector mechanisms. ACPA can use
multiple isotypes, and these ACPA isotypes are
already present before onset of RA [27]. In addition,
the number of different ACPA isotypes is predictive
for the development of radiological damage [28].
Similarly to the epitope-recognition profile, the
ACPA isotype profile appears not to expand any-
more during disease progression, indicating that
maturation of the ACPA response takes place before
onset of arthritis.
As mentioned above, the fragment crystalliz-
able (Fc) region of an antibody interacts with Fc
receptors of immune effector cells and the comp-
lement system, and thus determines which
immune effector mechanisms can be recruited by


























FIGURE 1. Maturation of the ACPA response. Antibodies reac
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1040-8711 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseregion of ACPA has been reported to be different
from non-ACPA IgG. The Fc region of ACPA-IgG1
contains reduced numbers of sialic acid and
galactose residues [29], a feature which is generally
considered to render IgG antibodies proinflamma-
tory [30
&
]. The changes in ACPA Fc glycosylation
pattern become more prominent around 3 months
before onset of RA [15
&&
]. Differences in glycosyla-
tion pattern between Ig isotypes might influence
their affinity for Fc receptors. A recent study [30
&
]
showed that ACPA-IgG1 has a different Fc-glycan
profile compared with non-CCP2 reactive IgG1, a
particularity which can influence the affinity of
ACPA IgG to Fc receptors and complement and
may modulate ACPA effector and immune-
regulatory functions [31].
In conclusion, all these different autoantibody
characteristics evolve and mature before disease
onset, and once patients present with arthritis,
the ACPA response is generally increased in titre,
uses more isotypes, displays a different glycosylation
pattern, and are cross-reactive towards different
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Role of ACPA in early diseaseHUMAN LEUCOCYTE ANTIGEN CLASS II
ASSOCIATIONS IN RHEUMATOID
ARTHRITIS
The most important genetic risk factor for ACPA-
positive RA is the HLA class II region. RA, like many
other autoimmune diseases, is characterized by a
strong association with variants in the HLA class II
region. These HLA associations differ in ACPA-





highlighting the complexity of pathogenic mechan-
isms underlying HLA associations in RA. The HLA
class II region encodes for HLA-DR, HLA-DQ and
HLA-DP proteins and is involved in antigen presen-
tation to HLA class II restricted CD4þ T-helper cells.
In 1976, analysis of mixed lymphocyte cultures from
RA patients revealed that these individuals had cer-
tain HLA-DR4 molecules in common [36]. The HLA
haplotypes that encode for the HLA-DR4 molecules
were found to be characterized by the so-called ‘HLA-
shared epitope (SE)’, a common amino-acid sequence
in the HLA-DRB1 chain [37]. Recent genome wide
analysis revealed specific amino acids at positions 11,
13, 71 and 74 of the HLA-DRB1 chain as well was
single-amino-acid polymorphismsatpositionnine of
HLA-B and HLA-DPB1 are associated with the greatest
risk for RA [38]. Amino-acid positions 11 and 13 of
HLA-DRB1 are among the most polymorphic and are
highly relevant for the shaping of peptide-binding
pockets located in peptide-binding groove of the HLA
molecule. It is therefore not surprisingly that the
statistically significant amino-acid positions are
those involved in peptide presentation.
The HLA-SE alleles are now known to be specifi-
cally associated with ACPA-positive RA [32,38].
Conversely, HLA-DRB113 alleles haplotypes have
been found to protect against the development of
ACPA-positive RA [33
&
,34]. A possible explanation
for the association of the ‘HLA-shared epitope’ with
ACPA-positive RA might be that peptide presen-
tation by the ‘HLA-shared epitope’ HLA molecules
can facilitate the activation of CD4þ T cells which
provide help to ACPA-producing B cells. In ACPA-
positive RA, ACPA are cross-reactive and bind to a
wide variety of citrullinated self-proteins which
indicates a loss of B-cell tolerance. However, it is
unclear to what extent T-cell tolerance is lost. Identi-
fication of citrullinated epitopes recognized by
autoreactive T cells in patients with RA has proven
difficult. Analysis using peptide-HLA tetramers and
in-vitro T-cell responses to candidate epitopes
revealed T-cell recognition of several citrullinated
epitopes in humans [39,40,41
&
,42].
The HLA-DRB113 alleles which are protective
for RA, carry a five amino-acid sequence called:
DERAA. The DERAA sequence is also expressed byyright © 2016 Wolters Kluwer Health, Inc. Unaut
4 www.co-rheumatology.commany microbes and in a self-protein vinculin.
Citrullinated vinculin is expressed in the inflamed
synovial membrane and was recently identified as a
novel autoantigen for ACPA antibodies [43]. It is
proposed that molecular mimicry of self-proteins
with pathogenic microbial proteins might lead to
a break of T-cell tolerance. Indeed, it was recently
shown, that T cells present in HLA-DRB113-
negative donors were able to specifically recognize
a DERAA-containing vinculin epitope that cross-
react with DERAA sequences derived from patho-
gens [44
&&
]. However, many T-cell responses are
absent in HLA-DR13þ donors, indicating the induc-
tion of DERAA-specific T-cell tolerance in these
donors. Together, these studies suggests that the
HLA class II locus can directly influence the matu-
ration of the ACPA response via antigen-specific
T cells, providing help to ACPA-producing B cells
and enabling the maturation of the citrullinated
protein-specific autoantibody response.PATHOGENIC ROLE OF THE IMMUNE
RESPONSE AGAINST CITRULLINATED
PROTEINS
Apart from the diagnostic application of ACPA as a
biomarker, several clinical observations suggest that
ACPA could play a direct role in disease pathology.
First, ACPA may be found early in the course of
disease, up to 7 years before RA manifests [5,6].
Second, various follow-up studies [45–47,48
&
]
revealed that ACPA-positive patients with recent-
onset RA develop more bone erosions compared
with ACPA-negative RA patients. Third, bone loss
and reduced bone mineral density can be found in
healthy ACPA-positive individuals, even before
clinical onset of arthritis [49
&
].
Selective B-cell depletion using rituximab has
been found to be effective in the treatment of RA
[50,51,52
&
], providing evidence for the involvement
of B cells in the pathogenesis of RA. ACPA-produc-
ing B cells are found to be enriched in synovial fluid
[21,53], which suggests that ACPA can be produced
locally and directly contribute to synovial inflam-
mation. Moreover, the numbers of ACPA-producing
B cells in the blood of RA patients correlate with
ACPA serum levels [54].
Functional studies showed that immune
complexes formed with ACPA mediate effector func-
tions via Fc-g receptors [55], and can induce comp-
lement activation [24] and enhanced neutrophil
extracellular trap formation [56]. In addition, there
are reports that purified ACPA can induce osteoclas-
togenesis and bone resorption in mice [57],
suggesting a direct link between ACPA and morehorized reproduction of this article is prohibited.
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tal studies succeeded in showing in vivo that ACPA
may facilitate the transition from autoimmunity to
inflammation. Transfer of antibodies specific to cit-
rullinated fibrinogen [58] and transfer of antibodies
targeting citrullinated-collagen [59] to mice with
mild experimental arthritis led to disease exacer-
bation. It is interesting that no other positive data
have been reported allowing that these two positive
papers are similar as the many nonreplicated pre-
clinical papers in other fields such as oncology [60].
RA patients receiving Abatacept show reduced
levels of ACPA and rheumatoid factor in response
to treatment [61
&
]. Moreover, a Swedish pharmaco-
therapy trial reported a decline of all ACPA levels
independent of the clinical response on disease
activity during the first 3 months of methotrexate
treatment [17
&&
]. However, effective treatment
of established arthritis does not necessarily lead
to reduced ACPA levels or a change in ACPA
composition. For example, a Canadian cohort in
early arthritis patients found that anti-CCP anti-
body fluctuations did not relate to clinical scores
such as disease activity scores and the presence
of erosions [62]. These findings suggest that auto-
antibody-producing B cells rather than the autoanti-
bodies produced may be responsible for disease
pathogenesis. Activated B cells secrete proinflamma-
tory cytokines, such as interleukin-6 and TNF, and
ACPA-producing B cells are found to be increased in
the inflamed synovial membrane [16
&
].
In addition to ACPA, other autoantibodies and/
or autoantibody-producing B cells may also be
involved in RA pathogenesis. Similarly to ACPA,
both rheumatoid factor and anti-CarP antibodies







]. Anti-CarP autoantibodies recognize car-
bamylated proteins containing a homocitrulline, a
posttranslational modification of lysine driven by
cyanate, and can be found in patients with ACPA-
negative RA. More recently, antibodies targeting
another posttranslational modification, malondial-
dehyde/acetaldehyde (MAA) adducts, are found to
be increased in RA patients and this antibody
response is associated with the presence of ACPA
[65
&&
]. Similarly to carbamylation, MAA adducts are
capable of the modification of a lysine. These find-
ings raise the question why RA patients produce
autoantibodies towards posttranslational modified
proteins and whether these autoantibodies are
implicated in disease pathogenesis. Further research
is needed to confirm the current observations of
anti-CarP antibodies in ACPA-negative and positive
RA patients, and to determine whether these bio-
markers can provide additional value next to the
CCP2 test.opyright © 2016 Wolters Kluwer Health, Inc. Una
1040-8711 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseCONCLUSION
ACPA have proven to be a very useful biomarker
for diagnosing RA and for predicting a severe disease
course. Future investigations on the role of ACPA,
other autoantibodies, and ACPA-producing B cells
in RA may provide further insight in and under-
standing of the underlying disease pathogenesis.
Follow-up studies of RA patients may provide useful
information on the fluctuation of ACPA levels
and changes in ACPA composition during disease
progression and treatment. Together, these obser-
vations may allow new approaches to treat RA at an
early, preclinical, stage of disease, and thus enable
prevention of the transition of autoimmunity
to inflammation and autoimmune disease.
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